Titan Pharmaceuticals, Inc. (TTNP): Marketing Mix Analysis [Dec-2025 Updated]

You're digging into the current marketing mix for Titan Pharmaceuticals, Inc. (TTNP) as we close out 2025, and honestly, the landscape has shifted dramatically since the days when Probuphine was the main event. Given the recent reverse merger completed in September 2025, and the prior sale of the U.S. rights to that implant, we need to look past legacy revenue streams. The Q2 2025 results showed an EPS of $-\text{0.65}$, which tells you the story isn't about current sales volume; it's about the underlying ProNeura technology platform and pipeline assets like the Nalmefene implant. So, while the four P's framework still helps us map out the strategy-especially how they plan to monetize that tech-the focus is now almost entirely on future licensing and development milestones, not direct product promotion. Let's break down what that means for Product, Place, Promotion, and Price right now.

Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Product

The product element for Titan Pharmaceuticals, Inc. (TTNP) centers on its proprietary drug delivery technology and the specific therapeutics developed using it, reflecting a strategic shift toward development-stage assets as of late 2025.

Probuphine: The primary commercial product, a subdermal buprenorphine implant for opioid dependence.

• Probuphine is approved in the United States, Canada, and the European Union ("EU") as Sixmo™ for the maintenance treatment of opioid use disorder (OUD).
• The indication is for clinically stable patients taking 8 mg or less a day of oral buprenorphine.
• Titan Pharmaceuticals discontinued U.S. commercialization in the fourth quarter of 2020.
• The U.S. product rights were subsequently sold in September 2023.
• Commercialization in the EU continues under another company that acquired the rights from Titan Pharmaceuticals.

ProNeura drug delivery platform: Proprietary long-term, continuous drug delivery technology.

This technology forms the core of Titan Pharmaceuticals' product strategy. It consists of a small, solid implant made from a mixture of ethylene-vinyl acetate ("EVA") and a drug substance, designed to be administered subdermally in a brief, outpatient procedure.

• The platform provides continuous drug release and non-fluctuating medication levels over a period of six months or longer, depending on the drug characteristics.
• The solid matrix formulation is intended to virtually eliminate the risk of accidental drug dumping.

Pipeline focus: Developing long-acting implants for other indications, like the Nalmefene implant for alcohol dependence.

Titan Pharmaceuticals is advancing therapeutics based on the ProNeura platform for other chronic diseases. The Nalmefene implant is a key focus area for OUD relapse prevention.

• The ProNeura-based Nalmefene implant is intended for the prevention of relapse following opioid detoxification in adults with OUD.
• The U.S. Food and Drug Administration ("FDA") cleared the Investigational New Drug ("IND") application for a Phase 1 study of the six-month or longer subdermal nalmefene formulation in July 2022.
• Development was supported by grant funding from the National Institute for Drug Addiction ("NIDA"), with an initial two-year grant of approximately $6.7 million.
• The second-year award provided approximately $6.1 million in funding for implant formulation development, cGMP manufacturing, and non-clinical studies.
• The Kappa Opioid Receptor Agonist Peptide Implant (TP-2021) is also being developed, with initial non-clinical studies assessing feasibility for chronic pruritus treatment.

Licensing model: Core strategy involves out-licensing products developed using the ProNeura platform.

The corporate strategy, particularly since the restructuring announced in October 2020, emphasizes focusing resources on ProNeura-based product development and exploring strategic alternatives, which includes out-licensing.

• The company retains full commercial rights to the Nalmefene implant product, suggesting a future out-licensing opportunity upon successful clinical progression.
• The company is exploring strategic alternatives, including potential acquisitions, mergers, or other business combinations, as evidenced by the proposed reverse merger with TalenTec Sdn. Bhd., where existing security holders of Titan are expected to own approximately 13.3% of the combined company post-completion.

Small molecule assets: Maintaining a portfolio of early-stage small molecule compounds.

While the primary focus is on the ProNeura platform, Titan Pharmaceuticals maintains an early-stage portfolio.

Here is a quick look at the key product and platform data as of the latest available filings and updates:

Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Place

The Place strategy for Titan Pharmaceuticals, Inc. (TTNP) is defined by the divestiture of its primary commercial asset and reliance on historical and residual licensing structures as of late 2025.

Commercialization partners:

• Titan Pharmaceuticals, Inc. discontinued commercialization of Probuphine in the United States during the fourth quarter of 2020.
• The rights to the United States product were sold in September 2023.
• Probuphine continues to be commercialized in the European Union as Sixmo™ by a different company that acquired the rights from Titan Pharmaceuticals, Inc.

Global reach:

Market access is segmented by territory, managed through prior licensing agreements, as Titan Pharmaceuticals, Inc. is currently focused on exploring strategic alternatives, including asset sales or licensing, following an announcement in December 2021.

Direct sales force:

Internal direct sales infrastructure for the primary product is minimal to non-existent, as commercialization activities in the U.S. were discontinued in Q4 2020 and the asset was sold in September 2023.

Controlled substance handling:

Distribution logistics for products like Probuphine, which is a Schedule III controlled substance, are governed by Drug Enforcement Administration (DEA) regulations. Non-compliance risks are quantified by potential federal fines.

• Current federal fine per infraction for controlled substance violations is cited as $15,691.
• DEA oversight requires adherence to rules for Schedules II-V medications.
• The Federal Supply Schedule (FSS) contract for Probuphine, effective January 15, 2020, had a five-year term, potentially concluding around January 2025.

Specialty pharmacy network:

Access for the product in the U.S. was previously managed through established distribution channels for patients suffering from opioid use disorder. As of June 30, 2025, Titan Pharmaceuticals, Inc. had 1,330,234 common shares issued and outstanding.

Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Promotion

You're looking at the promotional activities for Titan Pharmaceuticals, Inc. (TTNP) as of late 2025, right after a major corporate shift. Honestly, for a company in this stage, promotion isn't about flashy TV ads; it's about communicating milestones and stability to the right people. Here's the quick math on the financial context supporting their communication strategy.

Investor relations focus: Primary communication centers on corporate updates, clinical milestones, and financial stability.

• Corporate updates centered on the reverse merger completion on October 1, 2025, creating Black Titan Corporation.
• PubCo Ordinary Shares were anticipated to begin trading on Nasdaq on October 2, 2025.
• Financing activities communicated included a private placement of $600,000 on June 27, 2025, and $1 Million on April 11, 2025.
• The Q2 2025 Quarterly Results were filed on June 30, 2025.

Scientific publications: Promotion through data presentation at medical and scientific conferences.

While the ProNeura platform has seen past validation with Probuphine® approval in the US, EU, and Canada, the focus for promotion through data presentation in 2025 is less clear in the immediate results, though the company is advancing treatment for select chronic diseases. The company was advancing non-clinical assessment of TP-2021 and nalmefene as of December 2021.

Partner-led marketing: Commercial promotion and physician outreach are the responsibility of the licensing partners.

Titan Pharmaceuticals discontinued US commercialization of Probuphine® in Q4 2020 and sold the US product in September 2023. The EU commercialization of Probuphine (as Sixmo™) is handled by another company that acquired the rights from Titan. Titan originally used a partnership for US commercialization.

Digital presence: Maintaining a corporate website for pipeline and technology information.

The corporate website provides access to Investor Relations materials, including News/Events, SEC Filings, and Financials. The 2025 Annual Meeting of Stockholders took place on June 16, 2025. The platform technology, ProNeura®, is highlighted for providing continuous drug release over six months or longer.

Limited direct-to-consumer: Marketing efforts are primarily business-to-business (B2B) and physician-focused.

The focus on investor relations and partner-led commercialization suggests promotion is heavily weighted toward B2B and physician outreach, consistent with a development-stage company undergoing a merger, rather than broad direct-to-consumer campaigns. The company's leadership combines expertise in drug delivery technology and biopharmaceutical development.

Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Price

The pricing strategy for Titan Pharmaceuticals, Inc. has historically been defined by its partnership model rather than direct consumer sales, especially concerning its ProNeura-based products like Probuphine.

Royalty-based revenue: Pricing strategy is indirect, generating revenue primarily through royalties on partner net sales.

• Royalty rates on U.S. and Canadian net sales for Probuphine were structured to range from the mid-teens to low-twenties percent.
• The company received an upfront payment of $15.8 million upon the initial FDA approval of Probuphine.
• Total potential milestone payments from the initial partner were up to $215 million (or $165 million based on an earlier figure) plus tiered royalties.

Product cost: The price of Probuphine is set by the commercial partner, reflecting the specialty nature and administration cost.

While specific cost of goods sold data for Probuphine in 2025 is not available, the structure implies a significant margin capture by the commercial partner, given the high-value specialty drug positioning.

Reimbursement hurdles: Pricing must navigate complex U.S. and international payer reimbursement policies for addiction treatment.

Historical context from 2020 cited suboptimal reimbursement rates as a factor contributing to the decision to wind down U.S. commercialization activities, indicating that the net realized price after payer negotiations was a critical constraint on the pricing model.

Licensing fees: Revenue includes upfront and milestone payments from partners, not direct product sales price.

The most recent financial transactions reflect capital raising through preferred stock issuance rather than product-related milestone achievements, showing the company's focus on financing its ongoing operations as of late 2025:

The June 2025 transaction involved issuing 60,000 shares of Series C Convertible Preferred Stock at a price of $10.00 per share.

High-value specialty drug: Positioned as a premium, long-acting treatment option compared to daily oral medications.

Probuphine was designed to deliver buprenorphine continuously for six months, contrasting with daily sublingual formulations like Suboxone and Subutex, which had combined sales of about $1.3 billion in 2012, positioning the implant as a premium, lower-frequency treatment alternative.

The company's market capitalization as of November 2025 was reported as $6.13 million, with 1.33 million shares outstanding.